Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05100095RecruitingPhase 2
Radiation schedule study for Merkel cell skin cancer
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Houston, TexasAges 18 years+ - NCT05113537RecruitingPhase 1/Phase 2
Abemaciclib before PSMA cancer therapy for advanced prostate cancer
This trial tests whether taking abemaciclib before a PSMA-targeted radioligand can help people with advanced, treatment-resistant prostate cancer. The goal is to improve how well the PSMA therapy works while staying safe.
San Francisco, CaliforniaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT05028725Recruiting
Testing an esophagus sponge test for early cancer detection
This study checks whether a special sponge you swallow (EsophaCap) can help detect early esophageal cancer—or help sort out concerning symptoms. You may be contacted again 1–2 weeks later for a short interview.
Dar es Salaam, MloganzilaAges 18 years+ - NCT05023265Recruiting
Study quality of life after SBRT for kidney cancer
This trial studies how well people do—especially their quality of life—after SBRT radiation for primary kidney cancer that can’t be removed with surgery. It may help doctors understand which patients benefit most and what side effects to expect.
Toronto, OntarioAges 18 years+ - NCT05048212RecruitingPhase 2
Nivolumab, ipilimumab, and cabozantinib for kidney cancer brain spread
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
Houston, TexasAges 18 years+ - NCT04528420Recruiting
Early treatment plan for head and neck skin cancer
This study tests an optimized plan for treating squamous cell cancer in the head and neck area using curative treatment that includes chemotherapy with cisplatin plus radiation after surgery. It may help doctors improve early management and outcomes for people eligible for this standard approach.
AmiensAges 18–75 - NCT04944914RecruitingPhase 3
Camrelizumab with targeted radiation for limited nasopharyngeal cancer spread
This trial tests whether combining camrelizumab (an immune medicine) with stereotactic body radiotherapy (high-precision radiation) works better than camrelizumab alone. It’s for people whose nasopharyngeal cancer has spread to a small number of spots in the body and may help control those metastases longer.
Guangzhou, GuangdongAges 18–70 - NCT04965454RecruitingPhase 2
Testing immune treatment benefit based on beta-catenin activity in liver cancer
This Phase 2 trial studies whether a liver-cancer feature called beta-catenin activity can predict who benefits from immune checkpoint inhibitor treatment. If you may not be a good candidate for surgery or local therapies, the trial may help match the right patients to this type of immunotherapy.
Honolulu, HawaiiAges 18 years+ - NCT04970472Recruiting
Urothelial bladder cancer sample collection for adults
This trial collects clinical samples from adults who have suspected or confirmed urothelial (bladder/urinary tract lining) cancer. It helps researchers study the disease and may support future improvements in diagnosis or treatment.
ToulouseAges 18–99 - NCT04966481RecruitingPhase 3
Palbociclib plus cetuximab versus cetuximab alone
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
Worthington, MinnesotaAges 18 years+ - NCT04996914Recruiting
Radiation after chemo-embolization for liver cancer patients
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
Aachen, North Rhine-WestphaliaAges 18–80 - NCT04865939RecruitingPhase 3
Gemcitabine treatment compared with bladder wash in UTUC surgery
This Phase 3 trial studies whether using gemcitabine (a chemotherapy medicine) in the urinary tract better prevents cancer from coming back than using a simple water wash. It involves people with upper tract urothelial carcinoma who are having curative surgery to remove the affected ureter or kidney tube.
Dallas, TexasAges 18–90 - NCT04857502RecruitingEarly Phase 1
Tracking prostate cancer spread before lymph node surgery
This early study uses a special imaging tracer to show where prostate cancer has spread in the pelvic lymph nodes. It may help doctors better understand how well certain scans guide surgical removal of affected lymph nodes.
Los Angeles, CaliforniaAges Any age - NCT04912765RecruitingPhase 2
New immune vaccine plus nivolumab for liver cancer
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
SingaporeAges 21 years+ - NCT03894917Recruiting
Study blood and imaging features in older adults with liver cancer
This study looks at what liver cancer is like in newly diagnosed people who are older and whose cancer cannot be removed by surgery. It may help doctors better understand disease behavior and how treatments may work and affect the body.
San Antonio, TexasAges 18 years+ - NCT04852328RecruitingPhase 2
Testing CUE-101 schedules before treatment for HPV16 throat cancer
This Phase 2 trial studies different timing “schedules” of CUE-101 given before surgery or before chemoradiation for HPV16-positive oropharyngeal throat cancer. The goal is to see if CUE-101 can help the body respond better and potentially improve outcomes.
St Louis, MissouriAges 18 years+ - NCT04839614Recruiting
Weight-loss surgery plus uterus surgery for certain uterine lining conditions
This trial tests doing weight-loss surgery at the same time as laparoscopic uterus (womb) surgery for people with certain early uterine lining conditions. It may help lower risk from severe obesity while treating the uterine condition.
Boston, MassachusettsAges 18 years+ - NCT04796818Recruiting
MRI scan to track response in colorectal liver metastases
This study uses a special MRI scan to see how colorectal cancer in the liver responds to planned chemotherapy before and after surgery. It may help doctors better measure treatment success and plan care.
Houston, TexasAges 18 years+ - NCT04853342RecruitingPhase 3
Furmonertinib after lung tumor removal for EGFR-mutated lung cancer
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
Suzhou, JiangsuAges 18–75
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,124 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.